Exagen Inc. (XGN): R&D Expense
$6.25M
Year ended 2025-12-31
$6.47M
Trailing 12 months to 2026-06-30
-14.1%
3-year compound annual growth
+11.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.25M | +16.4% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $5.38M | +10.5% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $4.87M | -50.7% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $9.88M | +36.5% | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | $7.24M | +102.8% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $3.57M | +64.0% | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | $2.18M | +2.4% | 2021-03-16, From 2019-01-01 |
| 2018-12-31 | $2.12M | n/a | 2020-03-25, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Exagen Inc. (XGN) | 2025-12-31 | $6.25M | +16.4% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $50.26M | +2.8% |
| Biodesix Inc (BDSX) | 2025-12-31 | $12.00M | +25.5% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
Compare XGN, PSNL, BDSX, GRAL side by side · Screen every company in Services-Medical Laboratories ↗